Cochlear Limited reported its fiscal 2026 results on August 18, 2026, with sales revenue of $2.3 billion, up 2% in constant currency. Underlying net profit fell 22% to $322 million due to manufacturing inefficiencies and pricing challenges.
The company's new Nexa cochlear implant platform drove revenue growth of 6% in the second half, with free cash flow more than doubling year-over-year. Investors responded positively, pushing shares up 7.19% to $140.69.
Financial Performance
Cochlear's FY26 results reflected a challenging operating environment, with gross margin contracting 3 percentage points to 71%. Operating expenses increased 5% on a reported basis to $1,251 million, though comparable operating expenses declined 1%.
Business Segments
The cochlear implants segment generated $1,435 million in revenue, flat in constant currency despite a 5% increase in units sold. The services segment delivered stronger performance, with revenue up 6% in constant currency to $635 million.
Strategic Shift
Cochlear is shifting its strategy toward the 'medicalization' of adult hearing loss, aiming to establish severe hearing loss as a recognized chronic disease with standardized screening and reimbursement frameworks. The company's approach focuses on strengthening referral pathways through direct-to-consumer marketing and professional channel development.